MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Multiple system atrophy(MSA): Treatment"

  • 2023 International Congress

    Use of levodopa-carbidopa intestinal gel to treat a patient with multiple system atrophy (MSA)

    A. Ferreira, S. Marques, A. Vieira, M. Coelho, G. Carneiro, M. Rodrigues (Braga, Portugal)

    Objective: To describe a case report on the use of Levodopa-carbidopa intestinal gel (LCIG) to treat non-motor symptoms in a patient with multiple system atrophy (MSA) Background: There is no…
  • 2023 International Congress

    UMSARS versus laryngoscopy-based assessment of dysphagia

    N. El Fassi, A. Pavy-Le-Traon, E. Mouchon, O. Rascol, W. Meissner, A. Foubert-Saumier, Y. Gallois, S. Tessier, F. Ory-Magne, V. Woizard, M. Fabbri (Toulouse, France)

    Objective: To compare the Unified Multiple System Atrophy Rating Scale (UMSARS)   part I-item 2 with an ear/nose/throat (ENT) expert physician assessment. Background: Early and severe…
  • 2023 International Congress

    Identifying a path to improve diagnostic delay and access to care for PSP, CBS, and MSA

    M. Bruno, F. Ali, M. Dale, M. Schmidt, M. Comeau, C. Spears, J. Shurer (Honolulu, USA)

    Objective: To understand diagnosis and care experiences of patients and care partners living with progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and multiple system atrophy…
  • 2023 International Congress

    Analysis of the therapeutic potential of c-Abl inhibition in Multiple System Atrophy

    M. Werner, E. Bertin, A. Simmonet, E. Noé, P. Fernagut, J. Molina, K. Lowe, E. Bezard, J. Kordower (Atlanta, USA)

    Objective: IkT-148009 is a potent selective inhibitor of non-receptor Abelson Tyrosine Kinases (c-Abl kinases).  Our recent analysis of post-mortem brain tissue from patients with Multiple…
  • 2023 International Congress

    Baseline characteristics for patients with multiple system atrophy entering a randomized, controlled study of the anti-α-synuclein monoclonal antibody Lu AF82422

    W. Singer, A. Takeda, L. Kjærsgaard, J. Wiedemann, A. Berger, A. Varrone, A. Bidani, D. Meulien (Rochester, USA)

    Objective: Report baseline characteristics for patients with multiple system atrophy (MSA) entering a study to assess the safety and efficacy of alpha-synuclein (α-syn) monoclonal antibody…
  • 2023 International Congress

    A multiple-dose thorough QT study to evaluate the effect of ampreloxetine on cardiac repolarization in healthy subjects

    M. Borin, J. Kanodia, R. Graham, A. Lo, B. Zheng, D. Bourdet (South San Francisco, USA)

    Objective: To characterize the effect of therapeutic and supratherapeutic doses of ampreloxetine on cardiac repolarization in healthy subjects. Background: Ampreloxetine is a potent NE reuptake…
  • 2023 International Congress

    Determinants of care partner burden in atypical parkinsonian syndromes

    M. Ivancic, J. Shurer, M. Schmidt, V. Nesspor, M. Li, Y. Lin, R. Xu, G. Schumock, M. Sklerov, A. Pantelyat (Chapel Hill, USA)

    Objective: To understand the determinants of burden among people caring for individuals diagnosed with progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), or multiple system atrophy…
  • 2023 International Congress

    Short-term effect of continuous positive airway pressure in MSA patients with sleep disordered breathing

    G. Lazzeri, M. Houot, M. Patout, F. Cormier, M. Vidailhet, JC. Corvol, I. Arnulf, D. Grabli, P. Dodet (Milan, Italy)

    Objective: SBD are frequent in MSA, mainly represented by inspiratory stridor, obstructive and central sleep apnea/hypopnea syndrome (SAS), or hypopneaimpacting the quality of sleep. A…
  • 2023 International Congress

    An Analysis of Subgroups of Multiple System Atrophy Patients from Ampreloxetine Phase 3 Trials

    R. Freeman, I. Biaggioni, L. Norcliffe-Kaufmann, T. Guerin, R. Vickery, L. Manzanares, V. Iodice, M. Rudzińska-Bar, M. Pellecchia, H. Kaufmann (Boston, USA)

    Objective: To present results in the subset of patients with multiple system atrophy (MSA) and relevant MSA subgroups from two ampreloxetine phase 3 trials for…
  • 2023 International Congress

    Therapy-associated risk decision making in individuals with multiple system atrophy and Parkinson’s disease, THE YAMSA TRIAL

    A. Bernhardt, M. Oeller, I. Friedrich, E. Kocakavuk, E. Nachman, K. Peikert, M. Roderigo, A. Rossmann, T. Schröter, LO. Wilhelm, F. Gandor, J. Levin, A. Giese, A. Janzen, WH. Oertel (Munich, Germany)

    Objective: This study aimed to quantify the risk willingness of patients suffering from the α-synucleinopathies multiple system atrophy (MSA) and Parkinson's Disease (PD) and identify…
  • 1
  • 2
  • 3
  • …
  • 6
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
      • Effect of marijuana on Essential Tremor: A case report
      • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
      • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
      • Insulin dependent diabetes and hand tremor
      • Patients with Essential Tremor Live Longer than their Relatives
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2023 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley